Opendata, web and dolomites

StopAddict SIGNED

The game changer drug to cure alcohol use disorders

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 StopAddict project word cloud

Explore the words cloud of the StopAddict project. It provides you a very rough idea of what is the project "StopAddict" about.

decreasing    kt    patients    society    agency    suffer    lives    indirect    treatments    actions    disability    revolutionary    drug    generating    alcohol    college    uncontrolled    regulatory    jobs    billion    efficacy    worldwide    characterised    2009    poor    recovery    persons    pharma    man    implicated    direct    stopaddict    communities    leads    2018    disorders    unsuccessful    trial    clinical    therapies    context    consumption    117m    patient    create    licensing    therapeutics    damaging    updated    deals    kinnov    revenues    110    intensive    companies    fto    accepted    neuropsychopharmacology    2025    action    alcoholism    ip    cumulative    class    families    leader    newly    commercialisation    award    adjusted    burden    triple    social    french    achievement    situation    disease    70    2027    treatment    mise    expenses    mechanism    huge    save    granted    discovered    dead    aud    first    seeking    10    successful    continuous    283    132    life    smei2    million    addiction    400    people   

Project "StopAddict" data sheet

The following table provides information about the project.

Coordinator
KINNOV THERAPEUTICS 

Organization address
address: 3 ALLEE DU TITANE
city: Orleans
postcode: 45100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙432˙400 €
 EC max contribution 2˙402˙680 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-10-01   to  2021-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KINNOV THERAPEUTICS FR (Orleans) coordinator 2˙402˙680.00

Map

 Project objective

Alcohol use disorders (AUD) is a disease characterised by uncontrolled alcohol consumption. 283 million persons worldwide suffer from alcohol mise use which cause more than 3 million dead and 132.6 million disability-adjusted life years. Alcoholism has also huge damaging effects on families, communities and the overall society. Current drug therapies against AUD are unsuccessful due to poor efficacy and strong side effects. That situation leads to low patient recovery and only 10% of AUD people seeking for treatment. In this context, Kinnov-Therapeutics has developed a new revolutionary first-in-class drug allowing patients to control their alcohol consumption. KT-110 drug will highly impact the European burden of AUD by decreasing alcohol consumption on AUD patients by 70% leading to triple the number of AUD people seeking for treatments and save more than 5 million lives per year and several billion of social cost expenses. The efficacy of KT-110 is related to its action on a newly discovered pathway highly implicated in alcohol addiction. This major understanding of AUD addiction mechanism was granted the European college of neuropsychopharmacology Neuropsychopharmacology Award in 2009. After 20 years of intensive research and pre-clinical development, KT-110 has been accepted by the french regulatory agency for its first-in man phase II clinical trial by the end of 2018. This will be the main achievement of SMEi2 project. Moreover, all necessary actions for successful commercialisation to pharma companies (licensing deals) as well as continuous and updated IP and FTO issues are planned to be implemented during the SMEi2. Through StopAddict project KT-110 will become the next leader of AUD treatments by generating €117m of cumulative revenues between 2025-2027. Our project will also allow to create more than 400 direct and indirect European jobs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "STOPADDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "STOPADDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

MIGRATECH 4.0 (2019)

The revolution in micro-granulation technology for eco-friendly, production efficient, superior ceramic tiles

Read More  

AMBRPAY (2019)

Decentralized subscription payments with cryptocurrency

Read More  

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More